• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现吲哚-3-丁酸衍生物作为有效的组蛋白脱乙酰酶抑制剂。

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors.

作者信息

Chen Yiming, Zhang Lihui, Zhang Lin, Jiang Qixiao, Zhang Lei

机构信息

Department of Medicinal Chemistry, School of Pharmacy, Weifang Medical University, Weifang, Shandong, China.

School of Stomatology, Weifang Medical University, Weifang, Shandong, China.

出版信息

J Enzyme Inhib Med Chem. 2021 Dec;36(1):425-436. doi: 10.1080/14756366.2020.1870457.

DOI:10.1080/14756366.2020.1870457
PMID:33445997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7822065/
Abstract

In discovery of HDAC inhibitors (HDACIs) with improved anticancer potency, structural modification was performed on the previous derived indole-3-butyric acid derivative. Among all the synthesised compounds, molecule exhibited high HDAC inhibitory and antiproliferative potencies in the investigations. The IC values of against HDAC1, HDAC3, and HDAC6 were 13.9, 12.1, and 7.71 nM, respectively. In the cancer cell based screening, molecule showed increased antiproliferative activities in the inhibition of U937, U266, HepG2, A2780, and PNAC-1 cells compared with SAHA. In the HepG2 xenograft model, 50 mg/kg/d of could inhibit tumour growth in athymic mice compared with 100 mg/kg/d of SAHA. Induction of apoptosis was revealed to play an important role in the anticancer potency of molecule . Collectively, a HDACI () with high anticancer activity was discovered which can be utilised as a lead compound for further HDACI design.

摘要

在发现具有更高抗癌活性的组蛋白去乙酰化酶抑制剂(HDACIs)的过程中,对先前衍生的吲哚-3-丁酸衍生物进行了结构修饰。在所有合成的化合物中,分子 在研究中表现出高组蛋白去乙酰化酶抑制活性和抗增殖活性。其对HDAC1、HDAC3和HDAC6的IC 值分别为13.9、12.1和7.71 nM。在基于癌细胞的筛选中,与SAHA相比,分子 在抑制U937、U266、HepG2、A2780和PNAC-1细胞方面表现出增强的抗增殖活性。在HepG2异种移植模型中,与100 mg/kg/d的SAHA相比,50 mg/kg/d的 可抑制无胸腺小鼠的肿瘤生长。细胞凋亡的诱导在分子 的抗癌活性中发挥重要作用。总体而言,发现了一种具有高抗癌活性的组蛋白去乙酰化酶抑制剂( ),其可作为进一步设计组蛋白去乙酰化酶抑制剂的先导化合物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/439d7e6b6022/IENZ_A_1870457_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/db2b35c8c2c0/IENZ_A_1870457_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/984889658965/IENZ_A_1870457_SCH0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/d74e10b03c72/IENZ_A_1870457_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/1873f9fa3805/IENZ_A_1870457_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/439d7e6b6022/IENZ_A_1870457_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/db2b35c8c2c0/IENZ_A_1870457_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/984889658965/IENZ_A_1870457_SCH0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/d74e10b03c72/IENZ_A_1870457_F0002_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/1873f9fa3805/IENZ_A_1870457_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fb4/7822065/439d7e6b6022/IENZ_A_1870457_F0004_C.jpg

相似文献

1
Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors.发现吲哚-3-丁酸衍生物作为有效的组蛋白脱乙酰酶抑制剂。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):425-436. doi: 10.1080/14756366.2020.1870457.
2
Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.基于吲哚的羟肟酸衍生物的设计、合成及作为组蛋白去乙酰化酶抑制剂的生物评价。
Eur J Med Chem. 2022 Jan 5;227:113893. doi: 10.1016/j.ejmech.2021.113893. Epub 2021 Oct 2.
3
Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps.发现具有修饰的菲啶帽的有效组蛋白去乙酰化酶抑制剂。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):707-718. doi: 10.1080/14756366.2021.1892089.
4
Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.发现具有强效 I 类组蛋白去乙酰化酶抑制活性的含吲哚衍生物的脂肪族链羟酰胺。
Eur J Med Chem. 2018 Jan 1;143:792-805. doi: 10.1016/j.ejmech.2017.11.092. Epub 2017 Dec 5.
5
Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.具有强大体外和体内抗肿瘤活性的基于3-羟基肉桂酰胺的组蛋白去乙酰化酶抑制剂的研发
Eur J Med Chem. 2015 Jan 7;89:628-37. doi: 10.1016/j.ejmech.2014.10.077. Epub 2014 Oct 29.
6
Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.嘌呤/嘌呤同系物为基础的支架作为苯甲酰胺类 HDAC 抑制剂的新衍生物。
Eur J Med Chem. 2020 Jun 15;196:112291. doi: 10.1016/j.ejmech.2020.112291. Epub 2020 Apr 6.
7
Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.新型噻吩并[2,3-d]嘧啶酮类 2-氨基苯甲酰胺衍生物的设计、合成及生物评价作为有效的组蛋白去乙酰化酶(HDAC)抑制剂。
Eur J Med Chem. 2019 Jul 1;173:185-202. doi: 10.1016/j.ejmech.2019.04.017. Epub 2019 Apr 11.
8
Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.发现新型组蛋白去乙酰化酶抑制剂作为潜在的抗癌药物。
Bioorg Med Chem. 2021 Jul 15;42:116251. doi: 10.1016/j.bmc.2021.116251. Epub 2021 Jun 8.
9
Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity.新型吡啶基羟肟酸和 2'-氨基苯甲酰胺类组蛋白去乙酰化酶抑制剂:生化特性和抗癌活性。
ChemMedChem. 2021 Mar 18;16(6):989-999. doi: 10.1002/cmdc.202000854. Epub 2020 Dec 16.
10
Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.新型无连接基苯甲酰胺类强效和选择性 HDAC3 抑制剂的合成、生物评价及分子对接分析。
Bioorg Chem. 2021 Sep;114:105050. doi: 10.1016/j.bioorg.2021.105050. Epub 2021 Jun 4.

引用本文的文献

1
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups.组蛋白去乙酰化酶抑制作用的药物发现:锌结合基团的过去、现在与未来
Pharmaceuticals (Basel). 2025 Apr 16;18(4):577. doi: 10.3390/ph18040577.
2
Microbiota, mitochondria, and epigenetics in health and disease: converging pathways to solve the puzzle.健康与疾病中的微生物群、线粒体和表观遗传学:解决谜题的汇聚途径
Pflugers Arch. 2025 May;477(5):635-655. doi: 10.1007/s00424-025-03072-w. Epub 2025 Mar 20.
3
DDQ catalyzed oxidative lactonization of indole-3-butyric acids.

本文引用的文献

1
Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition.丙戊酸钠在糖尿病相关结直肠癌中的再利用:组蛋白去乙酰化酶抑制的作用。
Eur J Pharm Sci. 2018 Aug 30;121:188-199. doi: 10.1016/j.ejps.2018.05.026. Epub 2018 May 28.
2
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.用于急性髓系白血病的含变构酰肼的I类组蛋白去乙酰化酶抑制剂的研发
J Med Chem. 2016 Nov 10;59(21):9942-9959. doi: 10.1021/acs.jmedchem.6b01385. Epub 2016 Oct 26.
3
Discovery of N-hydroxy-4-(1H-indol-3-yl)butanamide as a histone deacetylase inhibitor.
2,3-二氯-5,6-二氰基-1,4-苯醌催化吲哚-3-丁酸的氧化内酯化反应。
RSC Adv. 2024 Aug 2;14(33):24207-24211. doi: 10.1039/d4ra05265j. eCollection 2024 Jul 26.
4
Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis.肠道微生物群在非酒精性脂肪性肝病发病机制中诱导表观遗传修饰。
Eng Life Sci. 2023 Jun 2;24(5):2300016. doi: 10.1002/elsc.202300016. eCollection 2024 May.
5
I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition.I13通过直接抑制BCR-ABL,克服了慢性髓性白血病中由T315I突变介导的耐药性。
Front Pharmacol. 2023 Apr 12;14:1183052. doi: 10.3389/fphar.2023.1183052. eCollection 2023.
6
Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells.组蛋白去乙酰化酶抑制剂I3诱导具有(8;21)或MLL基因易位的急性髓系白血病细胞及白血病干细胞样细胞分化。
J Oncol. 2022 Aug 28;2022:3345536. doi: 10.1155/2022/3345536. eCollection 2022.
7
The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements Epigenetic Modification.组蛋白去乙酰化酶抑制剂I1通过表观遗传修饰诱导具有MLL基因重排的急性白血病细胞分化。
Front Pharmacol. 2022 Apr 27;13:876076. doi: 10.3389/fphar.2022.876076. eCollection 2022.
8
The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells.组蛋白去乙酰化酶抑制剂I13诱导急性髓系白血病细胞及白血病干细胞样细胞的M2、M3和M5亚型分化。
Front Oncol. 2022 Apr 12;12:855570. doi: 10.3389/fonc.2022.855570. eCollection 2022.
N-羟基-4-(1H-吲哚-3-基)丁酰胺作为组蛋白去乙酰化酶抑制剂的发现。
Drug Discov Ther. 2016;10(3):163-6. doi: 10.5582/ddt.2016.01031. Epub 2016 May 7.
4
Histone deacetylase inhibitors: potent anti-leukemic agents.组蛋白去乙酰化酶抑制剂:强效抗白血病药物。
Curr Med Chem. 2015;22(17):2065-74. doi: 10.2174/0929867322666150416094720.
5
Auxin activity: Past, present, and future.生长素活性:过去、现在与未来。
Am J Bot. 2015 Feb;102(2):180-96. doi: 10.3732/ajb.1400285. Epub 2015 Jan 29.
6
Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.组蛋白去乙酰化酶抑制剂在癌症治疗中的趋势:同工酶选择性或多靶点策略。
Med Res Rev. 2015 Jan;35(1):63-84. doi: 10.1002/med.21320. Epub 2014 Apr 29.
7
Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.炎症的表观遗传调控:从广泛作用的组蛋白去乙酰化酶(HDAC)抑制剂到靶向特定 HDAC。
Inflammopharmacology. 2013 Aug;21(4):301-7. doi: 10.1007/s10787-012-0166-0. Epub 2013 Jan 23.
8
Panobinostat for the treatment of multiple myeloma.泊马度胺治疗多发性骨髓瘤。
Expert Opin Investig Drugs. 2012 May;21(5):733-47. doi: 10.1517/13543784.2012.668883. Epub 2012 Mar 12.
9
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.组蛋白去乙酰化酶抑制剂作为神经退行性疾病治疗药物的评估。
Methods Mol Biol. 2011;793:495-508. doi: 10.1007/978-1-61779-328-8_32.
10
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND).HIV-1 Tat 上调人类神经元中组蛋白去乙酰化酶-2(HDAC2)的表达:与 HIV 相关的神经认知障碍(HAND)有关。
Neurochem Int. 2011 May;58(6):656-64. doi: 10.1016/j.neuint.2011.02.004. Epub 2011 Feb 17.